Investigational drug · Phase 2
Galvokimig
Also called: UCB9741
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Galvokimig"
First trial start
2025
Dec 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Galvokimig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
- Atopic Dermatitis
- Non-cystic Fibrosis Bronchiectasis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · COPD · Cystic fibrosis · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Galvokimig" as an intervention, largest first.
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisPivotal-lookingRecruiting
NCT07725939 · 402 participants (planned) · Start Jul 27, 2026 · Primary completion Jun 29, 2029
Drug: Galvokimig; Placebo · For: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Sites: Encino, California; Westminster, California; Miami, Florida · 26 sites in all
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
NCT07720375 · 300 participants (planned) · Start Aug 5, 2026 · Primary completion Feb 28, 2029
Drug: Galvokimig; Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Newport Beach, California; Brandon, Florida; Plantation, Florida · 7 sites in all
- A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisPivotal-lookingActive, not recruiting
NCT07277660 · 165 participants · Start Dec 29, 2025 · Primary completion May 17, 2027
Drug: Galvokimig; Placebo · For: Atopic Dermatitis
Sites: Oceanside, California; Santa Monica, California; Boca Raton, Florida · 59 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from UCB.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.